🇺🇸 FDA
Pipeline program

Tevimbra 100 mg concentrate for solution for infusion

UC-GIG-2003

Phase 2 small_molecule active

Quick answer

Tevimbra 100 mg concentrate for solution for infusion for Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy. is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials